Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.18
OTCPK:IDRSF's Cash-to-Debt is ranked lower than
74% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. OTCPK:IDRSF: 1.18 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:IDRSF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.18  Med: 1.68 Max: 2.48
Current: 1.18
1.18
2.48
Equity-to-Asset 0.51
OTCPK:IDRSF's Equity-to-Asset is ranked lower than
70% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OTCPK:IDRSF: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:IDRSF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.54 Max: 0.58
Current: 0.51
0.51
0.58
Debt-to-Equity 0.73
OTCPK:IDRSF's Debt-to-Equity is ranked lower than
72% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. OTCPK:IDRSF: 0.73 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:IDRSF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.48  Med: 0.56 Max: 0.73
Current: 0.73
0.48
0.73
Debt-to-EBITDA -3.09
OTCPK:IDRSF's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. OTCPK:IDRSF: -3.09 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:IDRSF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.09  Med: 83.59 Max: 168.13
Current: -3.09
-3.09
168.13
Altman Z-Score: 1.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -112.23
OTCPK:IDRSF's Operating Margin % is ranked higher than
52% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. OTCPK:IDRSF: -112.23 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:IDRSF' s Operating Margin % Range Over the Past 10 Years
Min: -112.23  Med: -4.99 Max: -4.99
Current: -112.23
-112.23
-4.99
Net Margin % -118.33
OTCPK:IDRSF's Net Margin % is ranked higher than
52% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. OTCPK:IDRSF: -118.33 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:IDRSF' s Net Margin % Range Over the Past 10 Years
Min: -118.33  Med: -9.03 Max: -9.03
Current: -118.33
-118.33
-9.03
ROE % -30.35
OTCPK:IDRSF's ROE % is ranked higher than
62% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. OTCPK:IDRSF: -30.35 )
Ranked among companies with meaningful ROE % only.
OTCPK:IDRSF' s ROE % Range Over the Past 10 Years
Min: -65.42  Med: -33.85 Max: -2.27
Current: -30.35
-65.42
-2.27
ROA % -16.74
OTCPK:IDRSF's ROA % is ranked higher than
68% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. OTCPK:IDRSF: -16.74 )
Ranked among companies with meaningful ROA % only.
OTCPK:IDRSF' s ROA % Range Over the Past 10 Years
Min: -36.62  Med: -18.96 Max: -1.29
Current: -16.74
-36.62
-1.29
ROC (Joel Greenblatt) % -77.65
OTCPK:IDRSF's ROC (Joel Greenblatt) % is ranked higher than
69% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. OTCPK:IDRSF: -77.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:IDRSF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -204.08  Med: -103.68 Max: -3.28
Current: -77.65
-204.08
-3.28
GuruFocus has detected 1 Warning Sign with Idorsia Ltd OTCPK:IDRSF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:IDRSF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:IDRSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Idorsia Ltd does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:ACAD, SZSE:002603, NAS:CLVS, SZSE:000990, SHSE:600161, HKSE:00570, SZSE:300009, XTER:MOR, NAS:CBPO, XKRX:084990, NAS:HALO, NAS:ASND, NAS:PBYI, NAS:ANAB, NAS:FOLD, NYSE:EBS, XBRU:ARGX, SZSE:002821, XSWX:GALE, NAS:CRSP » details
Traded in other countries:19T.Germany, IDIA.Switzerland, 0RQE.UK,
Headquarter Location:Switzerland
Idorsia Ltd is a biopharmaceutical company specialized in the discovery, development and commercialization of molecule therapeutics to treat central nervous system, cardiovascular disorders, immunological disorders and orphan diseases.

Idorsia Ltd is an independent biopharmaceutical company specialized in the discovery, development and commercialization of small molecule therapeutics to treat central nervous system, cardiovascular disorders, immunological disorders and orphan diseases.

Ratios

vs
industry
vs
history
PB Ratio 2.97
IDRSF's PB Ratio is ranked lower than
55% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. IDRSF: 2.97 )
Ranked among companies with meaningful PB Ratio only.
IDRSF' s PB Ratio Range Over the Past 10 Years
Min: 2.96  Med: 4.12 Max: 5.69
Current: 2.97
2.96
5.69
PS Ratio 11.86
IDRSF's PS Ratio is ranked lower than
58% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IDRSF: 11.86 )
Ranked among companies with meaningful PS Ratio only.
IDRSF' s PS Ratio Range Over the Past 10 Years
Min: 11.81  Med: 16.71 Max: 22.44
Current: 11.86
11.81
22.44
EV-to-EBIT -10.84
IDRSF's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. IDRSF: -10.84 )
Ranked among companies with meaningful EV-to-EBIT only.
IDRSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.8  Med: -19 Max: -10.79
Current: -10.84
-31.8
-10.79
EV-to-EBITDA -11.96
IDRSF's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. IDRSF: -11.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDRSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.4  Med: -21.7 Max: -11.9
Current: -11.96
-38.4
-11.9
EV-to-Revenue 12.40
IDRSF's EV-to-Revenue is ranked lower than
54% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. IDRSF: 12.40 )
Ranked among companies with meaningful EV-to-Revenue only.
IDRSF' s EV-to-Revenue Range Over the Past 10 Years
Min: 12.6  Med: 15.7 Max: 20.8
Current: 12.4
12.6
20.8
Current Ratio 8.35
IDRSF's Current Ratio is ranked higher than
74% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. IDRSF: 8.35 )
Ranked among companies with meaningful Current Ratio only.
IDRSF' s Current Ratio Range Over the Past 10 Years
Min: 8.35  Med: 10.42 Max: 18.99
Current: 8.35
8.35
18.99
Quick Ratio 8.35
IDRSF's Quick Ratio is ranked higher than
75% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. IDRSF: 8.35 )
Ranked among companies with meaningful Quick Ratio only.
IDRSF' s Quick Ratio Range Over the Past 10 Years
Min: 8.35  Med: 10.42 Max: 18.99
Current: 8.35
8.35
18.99

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 33.13
IDRSF's Price-to-Net-Current-Asset-Value is ranked lower than
80% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. IDRSF: 33.13 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IDRSF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.4  Med: 9.79 Max: 46.64
Current: 33.13
6.4
46.64
Price-to-Tangible-Book 2.99
IDRSF's Price-to-Tangible-Book is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. IDRSF: 2.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IDRSF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.88  Med: 4.09 Max: 5.31
Current: 2.99
2.88
5.31
Price-to-Median-PS-Value 0.71
IDRSF's Price-to-Median-PS-Value is ranked lower than
53% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. IDRSF: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IDRSF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.71  Med: 1.05 Max: 1.15
Current: 0.71
0.71
1.15
Earnings Yield (Greenblatt) % -9.23
IDRSF's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. IDRSF: -9.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IDRSF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.27  Med: -5.3 Max: -3.1
Current: -9.23
-9.27
-3.1

More Statistics

Revenue (TTM) (Mil) $180.48
EPS (TTM) $ -1.73
Volatility45.31%
52-Week Range $17.48 - 33.02
Shares Outstanding (Mil)131.05

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

» More Articles for OTCPK:IDRSF

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}